Reviewing Profound Medical (NASDAQ:PROF) & INVO Bioscience (NASDAQ:INVO)

Profound Medical (NASDAQ:PROF) and INVO Bioscience (NASDAQ:INVO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Valuation & Earnings

This table compares Profound Medical and INVO Bioscience”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$10.68 million	19.15	-$28.57 million	($1.12)	-6.08
INVO Bioscience	$5.77 million	1.81	-$8.03 million	N/A	N/A

INVO Bioscience has lower revenue, but higher earnings than Profound Medical.

Profitability

This table compares Profound Medical and INVO Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profound Medical	-349.41%	-85.22%	-64.87%
INVO Bioscience	-122.79%	N/A	-36.94%

Volatility & Risk

Profound Medical has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, INVO Bioscience has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500.

Insider and Institutional Ownership

47.9% of Profound Medical shares are owned by institutional investors. Comparatively, 12.0% of INVO Bioscience shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by insiders. Comparatively, 3.5% of INVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Profound Medical and INVO Bioscience, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	0	0	2	1	3.33
INVO Bioscience	0	0	0	0	0.00

Profound Medical currently has a consensus price target of $14.25, indicating a potential upside of 109.25%. Given Profound Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Profound Medical is more favorable than INVO Bioscience.

Summary

Profound Medical beats INVO Bioscience on 7 of the 13 factors compared between the two stocks.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

About INVO Bioscience

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.